Senologie - Zeitschrift für Mammadiagnostik und -therapie 2025; 22(03): 234-247
DOI: 10.1055/a-2661-0366
Übersicht

Update Mammakarzinom 2024 Teil 2 – Patientinnen mit Frühstadien des Mammakarzinoms

Update Breast Cancer 2024 Part 2 – Patients with Early Stage Breast Cancer

Authors

  • Wolfgang Janni

    1   Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
  • Hans-Christian Kolberg

    2   Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany
  • Andreas D. Hartkopf

    3   Department of Gynecology and Obstetrics, Tübingen University Hospital, Tübingen, Germany
  • Tanja N. Fehm

    4   Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
    5   Center for Integrated Oncology (CIO Aachen, Bonn, Cologne, Düsseldorf), Düsseldorf, Germany
  • Manfred Welslau

    6   Onkologie Aschaffenburg, Aschaffenburg, Germany
  • Volkmar Müller

    7   Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
  • Florian Schütz

    8   Gynäkologie und Geburtshilfe, Diakonissen-Stiftungs-Krankenhaus, Speyer, Germany
  • Peter A. Fasching

    9   Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
    10   Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
  • Christian Jackisch

    11   Evangelische Kliniken Essen Mitte, Essen, Germany
  • Frederik Marme

    12   Universitätsmedizin Mannheim, Frauenklinik, Mannheim, Germany
  • Manuel Hörner

    9   Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
    10   Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
  • Katharina Keller

    9   Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
    10   Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
  • Chloë Goossens

    9   Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
    10   Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
  • Erik Belleville

    13   ClinSol GmbH & Co. KG, Würzburg, Germany
  • Michael Untch

    14   Clinic for Gynecology and Obstetrics, Breast Cancer Center, Gynecologic Oncology Center, Helios Klinikum Berlin Buch, Berlin, Germany
  • Marc Thill

    15   Agaplesion Markus Krankenhaus, Department of Gynecology and Gynecological Oncology, Frankfurt am Main, Germany
  • Hans Tesch

    16   Oncology Practice at Bethanien Hospital, Frankfurt am Main, Germany
  • Nina Ditsch

    17   Department of Gynecology and Obstetrics, University Hospital Augsburg, Augsburg, Germany
  • Michael P. Lux

    18   Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Paderborn, Germany
  • Maggie Banys-Paluchowski

    19   Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
  • Achim Wöckel

    20   Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany
  • Nadia Harbeck

    21   Breast Center, Department of Gynecology and Obstetrics and CCC Munich LMU, LMU University Hospital, Munich, Germany
  • Elmar Stickeler

    22   Department of Obstetrics and Gynecology, Center for Integrated Oncology (CIO Aachen, Bonn, Cologne, Düsseldorf), University Hospital of RWTH Aachen, Aachen, Germany
  • Rupert Bartsch

    23   Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria
  • Bahriye Aktas

    24   Department of Gynecology, University of Leipzig Medical Center, Leipzig, Germany
  • Andreas Schneeweiss

    25   National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany
  • Johannes Ettl

    26   Cancer Center Kempten/Allgäu, Klinikverbund Allgäu gGmbH, Department of Obstetrics and Gynecology and Department of Oncology and Palliative Care, Klinikverbund Allgäu, Klinik für Frauenheilkunde und Gynäkologie, Kempten, Germany
  • Florin-Andrei Taran

    27   Department of Gynecology and Obstetrics, University Hospital Freiburg, Freiburg, Germany
  • Diana Lüftner

    28   Immanuel Hospital Märkische Schweiz, Buckow, Germany & Medical University of Brandenburg Theodor-Fontane, Brandenburg, Germany
  • Rachel Würstlein

    21   Breast Center, Department of Gynecology and Obstetrics and CCC Munich LMU, LMU University Hospital, Munich, Germany
  • Julia C. Radosa

    29   Department of Gynecology and Obstetrics, Saarland University Hospital, Homburg, Germany
Preview

Zusammenfassung

Diese Übersichtsarbeit fasst die aktuellen Entwicklungen zur Behandlung von Patientinnen mit Frühstadien des Mammakarzinoms zusammen. Die meisten klinisch relevanten Veränderungen sind durch die Einführung der Immuncheckpoint-Inhibitoren bei Patientinnen mit triple-negativem Brustkrebs (TNBC) und der CDK4/6-Inhibitoren bei Patientinnen mit hormonrezeptorpositiven, HER2-negativen (HRpos/HER2neg) Tumoren und hohem Rückfallrisiko vollzogen worden. Hier entstehen zunehmend Daten mit einer längeren Nachbeobachtungszeit und Integration von translationalen Analysen, die neue Biomarker wie zirkulierende Tumor-DNA (ctDNA) bewerten. In dieser Übersichtsarbeit werden die neuesten Entwicklungen der letzten Monate zusammengefasst und in den jeweiligen Kontext eingeordnet.

Abstract

This review summarizes the latest developments for the treatment of patients with early-stage breast cancer. Most of the clinically relevant changes were the result of using immune checkpoint inhibitors to treat patients with triple-negative breast cancer (TNBC) and CDK4/6 inhibitors to treat patients with hormone receptor-positive, HER2-negative (HRpos/HER2neg) tumors and a high risk of recurrence. Recent studies are presenting more and more data with long follow-up times and integrating translational analyses to evaluate new biomarkers such as circulating tumor DNA (ctDNA). This review article summarizes the latest developments published in recent months and puts the findings in context.



Publication History

Received: 20 November 2024

Accepted after revision: 07 December 2024

Article published online:
24 September 2025

© 2025. This article was originally published by Thieme in Geburtsh Frauenheilk 2025; 85: 493–506 as an open access article under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany